Mobile-health Network Solutions

NasdaqCM:MNDR Stock Report

Market Cap: US$9.3m

Mobile-health Network Solutions Valuation

Is MNDR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MNDR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MNDR's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MNDR's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MNDR?

Key metric: As MNDR is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for MNDR. This is calculated by dividing MNDR's market cap by their current revenue.
What is MNDR's PS Ratio?
PS Ratio0.7x
SalesUS$13.97m
Market CapUS$9.32m

Price to Sales Ratio vs Peers

How does MNDR's PS Ratio compare to its peers?

The above table shows the PS ratio for MNDR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.3x
PRPO Precipio
0.5xn/aUS$8.9m
CMAX CareMax
0.003x26.0%US$2.8m
SYRA Syra Health
0.8xn/aUS$6.4m
ATIP ATI Physical Therapy
0.009x5.3%US$6.7m
MNDR Mobile-health Network Solutions
0.7x49.2%US$9.3m

Price-To-Sales vs Peers: MNDR is expensive based on its Price-To-Sales Ratio (0.7x) compared to the peer average (0.3x).

Price to Sales Ratio vs Industry

How does MNDR's PS Ratio compare vs other companies in the US Healthcare Industry?

31 CompaniesPrice / SalesEstimated GrowthMarket Cap
MCK McKesson
0.2x8.1%US$78.85b
CVS CVS Health
0.2x4.6%US$71.52b
COR Cencora
0.2x6.4%US$47.67b
CNC Centene
0.2x5.5%US$29.84b
MNDR 0.7xIndustry Avg. 1.0xNo. of Companies31PS012345+
31 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: MNDR is good value based on its Price-To-Sales Ratio (0.7x) compared to the US Healthcare industry average (1x).

Price to Sales Ratio vs Fair Ratio

What is MNDR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MNDR PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.7x
Fair PS Ratio1x

Price-To-Sales vs Fair Ratio: MNDR is good value based on its Price-To-Sales Ratio (0.7x) compared to the estimated Fair Price-To-Sales Ratio (1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Lantheus Holdings

US$6.0b

Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.

LNTH

US$87.32

7D

8.0%

1Y

27.8%

Centene

US$29.8b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

CNC

US$60.35

7D

2.8%

1Y

-18.7%

electroCore

US$64.1m

A commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally.

ECOR

US$9.92

7D

-27.1%

1Y

80.4%